Kasey R. Skinner

Kasey R. Skinner

Auto-generated profile, based on publicly available information

Kasey R. Skinner

University of Alabama Birmingham

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
HRHasibur Rehman
Hasibur Rehman
DCDarshan Shimoga Chandrashekar
Darshan Shimoga Chandrashekar
CBChakravarthi Balabhadrapatruni
Chakravarthi Balabhadrapatruni
SNSaroj Nepal
Saroj Nepal
SBSai Akshaya Hodigere Balasubramanya
Sai Akshaya Hodigere Balasubramanya
JFJames E. Ferguson
James E. Ferguson
Metastatic urothelial carcinoma is generally incurable with current systemic therapies. Chromatin modifiers are frequently mutated in bladder cancer, with ARID1A -inactivating mutations present in about 20% of tumors. EZH2, a histone methyltransferase, acts as an oncogene that functionally opposes ARID1A. In addition, PI3K signaling is activated in more than 20% of bladder cancers. Using a combination of in vitro and in vivo data, including patient-derived xenografts, we show that ARID1A-mutant tumors were more sensitive to EZH2 inhibition than ARID1A WT tumors. Mechanistic studies revealed that (a) ARID1A deficiency results in a dependency on PI3K/AKT/mTOR signaling via upregulation of a noncanonical PI3K regulatory subunit, PIK3R3, and downregulation of MAPK signaling and (b) EZH2 inhibitor sensitivity is due to upregulation of PIK3IP1, a protein inhibitor of PI3K signaling. We show that PIK3IP1 inhibited PI3K signaling by inducing proteasomal degradation of PIK3R3. Furthermore, ARID1A-deficient bladder cancer was sensitive to combination therapies with EZH2 and PI3K inhibitors in a synergistic manner. Thus, our studies suggest that bladder cancers with ARID1A mutations can be treated with inhibitors of EZH2 and/or PI3K and revealed mechanistic insights into the role of noncanonical PI3K constituents in bladder cancer biology.

19 September 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
BLBenjamin Lin
Benjamin Lin
JZJulia Ziebro
Julia Ziebro
ESErin Smithberger
Erin Smithberger
KSKasey R Skinner
Kasey R Skinner
EZEva Zhao
Eva Zhao
CMC Ryan Miller
C Ryan Miller
The Lazarus effect is a rare condition that happens when someone seemingly dead shows signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal neoplasm glioblastoma (GBM) that through a series of negative clinical trials has prompted a vocal subset of the neuro-oncology community to declare this target dead. However, an argument can be made that the core tenets of precision oncology were overlooked in the initial clinical enthusiasm over EGFR as a therapeutic target in GBM. Namely, the wrong drugs were tested on the wrong patients at the wrong time. Furthermore, new insights into the biology of EGFR in GBM vis-à-vis other EGFR-driven neoplasms, such as non-small cell lung cancer, and development of novel GBM-specific EGFR therapeutics resurrects this target for future studies. Here, we will examine the distinct EGFR biology in GBM, how it exacerbates the challenge of treating a CNS neoplasm, how these unique challenges have influenced past and present EGFR-targeted therapeutic design and clinical trials, and what adjustments are needed to therapeutically exploit EGFR in this devastating disease.

24 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKasey R. Skinner
Kasey R. Skinner
TKTomoyuki Koga
Tomoyuki Koga
SMShunichiro Miki
Shunichiro Miki
RGRobert F. Gruener
Robert F. Gruener
FGFlorina-Nicoleta Grigore
Florina-Nicoleta Grigore
FFFrank B. Furnari
Frank B. Furnari
Diffuse midline glioma (DMG) is a leading cause of brain tumor death in children. In addition to hallmark H3.3K27M mutations, significant subsets also harbor alterations of other genes, such as TP53 and PDGFRA . Despite the prevalence of H3.3K27M, the results of clinical trials in DMG have been mixed, possibly due to the lack of models recapitulating its genetic heterogeneity. To address this gap, we developed human iPSC-derived tumor models harboring TP53 R248Q with or without heterozygous H3.3K27M and/or PDGFRA D842V overexpression. The combination of H3.3K27M and PDGFRA D842V resulted in more proliferative tumors when gene-edited neural progenitor (NP) cells were implanted into mouse brains compared to NP with either mutation alone. Transcriptomic comparison of tumors and their NP cells of origin identified conserved JAK/STAT pathway activation across genotypes as characteristic of malignant transformation. Conversely, integrated genome-wide epigenomic and transcriptomic analyses, as well as rational pharmacologic inhibition, revealed targetable vulnerabilities unique to the TP53 R248Q ; H3.3K27M; PDGFRA D842V tumors and related to their aggressive growth phenotype. These include AREG -mediated cell cycle control, altered metabolism, and vulnerability to combination ONC201/trametinib treatment. Taken together, these data suggest that cooperation between H3.3K27M and PDGFRA influences tumor biology, underscoring the need for better molecular stratification in DMG clinical trials.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
KSKasey Skinner
Kasey Skinner
TKTomoyuki Koga
Tomoyuki Koga
SMShunichiro Miki
Shunichiro Miki
RGRobert F. Gruener
Robert F. Gruener
RHR. Stephanie Huang
R. Stephanie Huang
RMRyan Miller
Ryan Miller
Diffuse intrinsic pontine glioma (DIPG) is a subset of high-grade glioma that occurs predominantly in children and has no cure. Up to 80% of DIPG harbor a heterozygous point mutation that results in a lysine 27 to methionine substitution in histone variant H3.3 (H3.3K27M). However, H3.3K27M alone is insufficient for tumorigenesis in existing DIPG models, suggesting that it interacts with co-occurring oncogenic mutations. NF1 deletion co-occurs with TP53 mutation and H3.3K27M in DIPG, but the impact of these mutations individually and together are understudied. To address this gap, we designed a model of DIPG based on human induced pluripotent stem cells (iPSC) edited via CRISPR to express either wild-type or deleted NF1 in conjunction with heterozygous H3.3K27M and a loss of function mutation in TP53. Edited iPSC were chemically differentiated into neural progenitor cells (iNPC), which upon implantation into the brainstems of immunodeficient mice formed diffusely invasive tumors that were histologically consistent with high-grade glioma. Mice with TP53mut;H3.3K27M tumors survived significantly (p<0.05) longer than those harboring TP53mut;NF1-/-;H3.3K27M tumors. In vitro proliferation assays of neurospheres generated from these tumors (termed iDIPG) confirmed this result, suggesting that NF1 deletion synergizes with the other two mutations to accelerate tumor growth. To determine which transcriptional pathways could be involved in this faster tumorigenesis, we performed RNA-sequencing TP53mut;H3.3K27M (TK) and TP53mut;NF1-/-;H3.3WT (TNK) iDIPG neurospheres as well as their iNPC precursors. iDIPG and iNPC clustered by NF1 status. Differential expression analysis comparing TNK and TK iDIPG neurospheres revealed 7226 differentially expressed genes (p<0.05). Gene set enrichment analysis showed upregulation of transcriptional programs related to cell cycle and kinase signaling cascades in TNK iDIPG neurospheres; therefore, we focused our analysis on differentially expressed kinases to determine whether NF1 deletion significantly impacts expression of the kinome. We found 141 kinases upregulated in TNK iDIPG neurospheres, including several members of the MAP kinase family and EGFR, which is amplified or activated in a large number of high-grade gliomas and therefore represents an attractive therapeutic target. Taken together, these data show that NF1 deletion is associated with a significant alteration of kinase expression in H3.3K27M iDIPG, potentially opening up a new therapeutic avenue in these devastating tumors. Further work using this model will focus on screening for kinases necessary for TNK iDIPG neurospheres survival in culture and investigating synergy between targeted kinase inhibition and HDAC inhibitors, which have shown promise in H3.3K27M DIPG. Citation Format: Kasey Skinner, Tomoyuki Koga, Shunichiro Miki, Robert F. Gruener, R. Stephanie Huang, Frank Furnari, Ryan Miller. NF1 deletion potentiates tumorigenesis and activates expression of cancer-related kinases in an iPSC-based model of H3.3K27M diffuse intrinsic pontine glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB067.

18 December 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
KSKasey R Skinner
Kasey R Skinner
LNLouis Nabors
Louis Nabors
CMC Ryan Miller
C Ryan Miller
Diffusely invasive glioma, the most common and malignant primary brain tumor, comprises a diverse group of diseases. These tumors range from lower-grade astrocytomas and oligodendrogliomas (grades II and III) to the deadly glioblastoma (GBM, grade IV) when diagnosed based on the current World Health Organization (WHO) classification.1 GBM has historically been treated as a single disease on the basis of histological criteria; however, advances in molecular technology and the advent of next-generation sequencing have revealed significant heterogeneity both within and among tumors. In 1999, the NCI Director’s Challenge asked “the scientific community to harness the power of comprehensive molecular analysis technologies to make the classification of tumors vastly more informative.” In response, The Cancer Genome Atlas (TCGA) and others identified mutational drivers in GBM and classified tumors into subtypes according to gene expression. Alterations in tumor suppressors such as CDKN2A, TP53, and PTEN and oncogenes including EGFR were among those most frequently found, delineating signaling pathways commonly affected in this disease.2 Additionally, tumors harboring point mutations in the genes encoding isocitrate dehydrogenase (IDH1 or IDH2) were found to be associated with longer survival than their IDH wild-type (IDHwt) counterparts.3 Because of these newly discovered genomic alterations and their implications for the clinic, the 2016 WHO classification of central nervous system tumors was historic in that it included both molecular and histological criteria for the diagnosis of GBM.1

9 November 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
TKTomoyuki Koga
Tomoyuki Koga
SMShunichiro Miki
Shunichiro Miki
KSKasey R Skinner
Kasey R Skinner
SVSriram Venneti
Sriram Venneti
DMDenise Malicki
Denise Malicki
FFFrank Furnari
Frank Furnari
Diffuse midline glioma is the leading cause of brain tumor death among the pediatric population. Drugs that show notable promise in preclinical models inevitably fail to demonstrate efficacy in clinical trials, likely due to the inadequacy of preclinical models. We have recently proposed glioblastoma models derived from human induced pluripotent stem cells (hiPSCs) genetically engineered with different combinations of glioblastoma-associated genetic alterations as a platform to search for therapeutic targets. These glioblastoma avatars authentically recapitulated the different pathobiology of glioblastoma subtypes, depending on what genetic alterations to be introduced. To investigate the biology and to develop novel therapeutics for diffuse midline glioma with H3K27M mutation, we have established a novel model by introducing H3.3 K27M mutation together with one of the most common concurrent genetic alterations, TP53 R248Q mutation, into hiPSCs through CRISPR/Cas9 genome engineering. Orthotopic engraftment of the neural progenitor cells derived from these edited hiPSCs formed diffusely invasive brainstem tumors with histological features of the diffuse midline glioma. These tumor avatars presented a global reduction in H3K27me3 accompanied by the expression of H3K27M. Transcriptome analyses of these models revealed that these avatars with H3K27M cluster apart from the pediatric glioma samples without this particular mutation, and that they present signatures of oligodendroglial progenitor differentiation as discovered in patient samples with this mutation. Using these models faithfully recapitulating histology and pathobiology of the patient tumors, we have performed drug screening and confirmed that their sensitivity to known drugs, including an EZH2 inhibitor and histone deacetylase inhibitors. On these faithful human avatars of diffuse midline glioma with H3K27M, we have applied bioinformatics algorithms of drug sensitivity prediction aiming at developing novel therapeutics for this devastating pediatric glioma.